Medicus Pharma Ltd
MDCX2.300USD
+0.100+4.55%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
36.65MMarket Cap
LossP/E TTM
More Details of Medicus Pharma Ltd Company
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
Medicus Pharma Ltd Info
Ticker SymbolMDCX
Company nameMedicus Pharma Ltd
IPO dateOct 11, 2023
CEODr. Raza Bokhari, M.D.
Number of employees12
Security typeOrdinary Share
Fiscal year-endOct 11
Address100 King Street West
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM5X 1A4
Phone17323003046
Websitehttps://medicuspharma.com/
Ticker SymbolMDCX
IPO dateOct 11, 2023
CEODr. Raza Bokhari, M.D.
Company Executives of Medicus Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President, Acting Chief Financial Officer
President, Acting Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
--
--
Mr. Frank W. Lavelle
Mr. Frank W. Lavelle
Independent Director
Independent Director
--
--
Dr. Sara R. May, Ph.D.
Dr. Sara R. May, Ph.D.
Director
Director
--
--
Mr. Barry Fishman, CPA
Mr. Barry Fishman, CPA
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President, Acting Chief Financial Officer
President, Acting Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Oct 30
Updated: Thu, Oct 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Velocity Fund Partners LP
13.23%
215 Capital Togo PHL Fund I, LP
9.32%
Interchange Capital Partners LLC
7.40%
Hathaway (John)
3.73%
Bokhari (Raza)
3.70%
Other
62.62%
Shareholders
Shareholders
Proportion
Velocity Fund Partners LP
13.23%
215 Capital Togo PHL Fund I, LP
9.32%
Interchange Capital Partners LLC
7.40%
Hathaway (John)
3.73%
Bokhari (Raza)
3.70%
Other
62.62%
Shareholder Types
Shareholders
Proportion
Corporation
22.55%
Individual Investor
11.46%
Investment Advisor
9.06%
Hedge Fund
0.44%
Bank and Trust
0.12%
Research Firm
0.07%
Investment Advisor/Hedge Fund
0.02%
Other
56.28%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
28
2.08M
9.71%
-1.07M
2025Q2
22
10.21M
64.09%
+108.37K
2025Q1
19
10.07M
84.39%
+1.61M
2024Q4
12
8.43M
77.76%
+1.48M
2024Q3
8
6.05M
68.59%
+2.33M
2024Q2
7
4.05M
50.15%
+329.10K
2024Q1
9
3.82M
47.35%
+3.82M
2023Q4
9
3.82M
47.35%
+3.82M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Velocity Fund Partners LP
2.84M
14.04%
--
--
Jun 30, 2025
215 Capital Togo PHL Fund I, LP
2.00M
9.89%
--
--
Sep 22, 2025
Interchange Capital Partners LLC
1.59M
7.85%
-75.00K
-4.51%
Jun 30, 2025
Hathaway (John)
800.95K
3.96%
--
--
Jun 30, 2025
Bokhari (Raza)
793.17K
3.92%
--
--
Sep 22, 2025
Melani (Kenneth)
409.41K
2.02%
--
--
Jun 30, 2025
Quinlan (James P)
274.15K
1.36%
--
--
Sep 22, 2025
Private Advisor Group LLC
146.00K
0.72%
+89.25K
+157.27%
Jun 30, 2025
Brennan (Edward Joseph JR)
86.50K
0.43%
--
--
Sep 22, 2025
Verition Fund Management LLC
53.38K
0.26%
+53.38K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
